7utg
From Proteopedia
(Difference between revisions)
(New page: '''Unreleased structure''' The entry 7utg is ON HOLD until Paper Publication Authors: Laura, M.K.D., Liting, Z. Description: 2D9 nanobody to BCL11A-exZF23 fragment [[Category: Unreleas...) |
|||
| (3 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==2D9 nanobody to BCL11A-exZF23 fragment== | |
| + | <StructureSection load='7utg' size='340' side='right'caption='[[7utg]], [[Resolution|resolution]] 1.25Å' scene=''> | ||
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[7utg]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Vicugna_pacos Vicugna pacos]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7UTG OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7UTG FirstGlance]. <br> | ||
| + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.25Å</td></tr> | ||
| + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7utg FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7utg OCA], [https://pdbe.org/7utg PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7utg RCSB], [https://www.ebi.ac.uk/pdbsum/7utg PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7utg ProSAT]</span></td></tr> | ||
| + | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Proximity-based strategies to degrade proteins have enormous therapeutic potential in medicine, but the technologies are limited to proteins for which small molecule ligands exist. The identification of such ligands for therapeutically relevant but "undruggable" proteins remains challenging. Herein, we employed yeast surface display of synthetic nanobodies to identify a protein ligand selective for BCL11A, a critical repressor of fetal globin gene transcription. Fusion of the nanobody to a cell-permeant miniature protein and an E3 adaptor creates a degrader that depletes cellular BCL11A in differentiated primary erythroid precursor cells, thereby inducing the expression of fetal hemoglobin, a modifier of clinical severity of sickle cell disease and beta-thalassemia. Our strategy provides a means of fetal hemoglobin induction through reversible, temporal modulation of BCL11A. Additionally, it establishes a new paradigm for the targeted degradation of previously intractable proteins. | ||
| - | + | A Cell-Permeant Nanobody-Based Degrader That Induces Fetal Hemoglobin.,Shen F, Zheng G, Setegne M, Tenglin K, Izadi M, Xie H, Zhai L, Orkin SH, Dassama LMK ACS Cent Sci. 2022 Dec 28;8(12):1695-1703. doi: 10.1021/acscentsci.2c00998. Epub , 2022 Dec 14. PMID:36589886<ref>PMID:36589886</ref> | |
| - | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
| - | [[Category: | + | </div> |
| - | [[Category: | + | <div class="pdbe-citations 7utg" style="background-color:#fffaf0;"></div> |
| - | [[Category: | + | == References == |
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Large Structures]] | ||
| + | [[Category: Vicugna pacos]] | ||
| + | [[Category: Dassama LMK]] | ||
| + | [[Category: Zhai L]] | ||
Current revision
2D9 nanobody to BCL11A-exZF23 fragment
| |||||||||||
